Hemgenix
-
King of Prussia’s CSL Behring Pioneers Gene Therapy Changing Hemophilia Care
King of Prussia–based CSL Behring is at the center of a medical breakthrough that’s reshaping life for people with hemophilia,…
-
FDA Approves CSL Behring Marketing of Hemophilia B Gene Therapy; Its $3.5M List Price Is a Record
The Food and Drug Administration has awarded King of Prussia-based CSL Behring marketing approval for Hemgenix, the first hemophilia B…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
